Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. (4th May 2022)

Record Type:: Journal Article
Title:: Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. (4th May 2022)
Main Title:: Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan
Authors:: Feemster, Kristen A.
Kim, Youngju
Abe, Machiko
Johnson, Kelly
Sasaki, Shin
Abstract:
Is Part Of:: Expert review of vaccines. Volume 21:Number 5(2022)
Journal:: Expert review of vaccines
Issue:: Volume 21:Number 5(2022)
Issue Display:: Volume 21, Issue 5 (2022)
Year:: 2022
Volume:: 21
Issue:: 5
Issue Sort Value:: 2022-0021-0005-0000
Page Start:: 589
Page End:: 590
Publication Date:: 2022-05-04
Subjects:: Pneumococcal -- vaccine -- immunity
Vaccines -- Periodicals
Vaccination -- Periodicals
615.37205
Journal URLs:: http://informahealthcare.com/toc/erv/current ↗
http://www.future-drugs.com/loi/erv ↗
http://informahealthcare.com ↗
DOI:: 10.1080/14760584.2022.2036127 ↗
Languages:: English
ISSNs:: 1476-0584
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 3842.002998
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store
Ingest File:: 21439.xml